Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07363486 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Name: Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer — clinical trial record (NCT07363486)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1/2

SponsorFirst Affiliated Hospital of Fujian Medical University

Started2025-04-01

View on ClinicalTrials.gov ↗

First Affiliated Hospital of Fujian Medical University

56 trials monitored

See all monitored trials

Prostate Cancer

2,471 trials monitored

See 156 trials at risk

PSMA is an ideal target for the precise diagnosis and treatment of prostate cancer. LNC1011 is a novel albumin-binding PSMA-targeted compound. This study aims to investigate the safety and efficacy of different doses of 225Ac-labeled LNC1011 in the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) and to explore the optimal therapeutic dose.

Trial Details

NCT Number	NCT07363486
Lead Sponsor	First Affiliated Hospital of Fujian Medical University
Conditions	Prostate Cancer
Enrollment	9 participants
Start Date	2025-04-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-23